A Systematic Review of Immune Checkpoint Inhibitor–Associated Glomerular Disease

Darvin, 2018, Immune checkpoint inhibitors: recent progress and potential biomarkers, Exp Mol Med, 50, 1, 10.1038/s12276-018-0191-1

Weber, 2010, Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade, Semin Oncol, 37, 430, 10.1053/j.seminoncol.2010.09.005

Callahan, 2018, Nivolumab plus ipilimumab in patients with advanced melanoma: updated survival, response, and safety data in a phase I dose-escalation study, J Clin Oncol, 36, 391, 10.1200/JCO.2017.72.2850

Flippot, 2018, Immune checkpoint inhibitors: toward new paradigms in renal cell carcinoma, Drugs, 78, 1443, 10.1007/s40265-018-0970-y

Garon, 2015, Pembrolizumab for the treatment of non-small-cell lung cancer, N Engl J Med, 372, 2018, 10.1056/NEJMoa1501824

Ghatalia, 2020, Integration of immunotherapy into the treatment of advanced urothelial carcinoma, J Natl Compr Canc Netw, 18, 355, 10.6004/jnccn.2020.7539

Motzer, 2015, Nivolumab versus everolimus in advanced renal-cell carcinoma, N Engl J Med, 373, 1803, 10.1056/NEJMoa1510665

Yokota, 2019, Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study, J Dermatol, 46, 1197, 10.1111/1346-8138.15103

Postow, 2018, Immune-related adverse events associated with immune checkpoint blockade, N Engl J Med, 378, 158, 10.1056/NEJMra1703481

Abdel-Wahab, 2018, Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review, Ann Intern Med, 168, 121, 10.7326/M17-2073

Izzedine, 2017, Renal effects of immune checkpoint inhibitors, Nephrol Dial Transplant, 32, 936

Jhaveri, 2019, Adverse events associated with immune checkpoint inhibitors, JAMA, 321, 1218, 10.1001/jama.2018.22114

Mamlouk, 2019, Cancer immunotherapy and its renal effects, Journal of Onco-Nephrology, 3, 151, 10.1177/2399369319866837

Murakami, 2017, Renal complications of immune checkpoint blockade, Curr Probl Cancer, 41, 100, 10.1016/j.currproblcancer.2016.12.004

Perazella, 2016, Checkmate: kidney injury associated with targeted cancer immunotherapy, Kidney Int, 90, 474, 10.1016/j.kint.2016.05.024

Perazella, 2020, Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?, Kidney Int, 97, 62, 10.1016/j.kint.2019.07.022

Sury, 2018, Cardiorenal complications of immune checkpoint inhibitors, Nat Rev Nephrol, 14, 571, 10.1038/s41581-018-0035-1

Wanchoo, 2017, Adverse renal effects of immune checkpoint inhibitors: a narrative review, Am J Nephrol, 45, 160, 10.1159/000455014

Cortazar, 2016, Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors, Kidney Int, 90, 638, 10.1016/j.kint.2016.04.008

Seethapathy, 2019, The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors, Clin J Am Soc Nephrol, 14, 1692, 10.2215/CJN.00990119

Belliere, 2016, Acute interstitial nephritis related to immune checkpoint inhibitors, Br J Cancer, 115, 1457, 10.1038/bjc.2016.358

Bottlaender, 2017, Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma, J Immunother Cancer, 5, 57, 10.1186/s40425-017-0261-2

de Sousa Oliveira, 2019, Interstitial nephritis associated with nivolumab in a patient with hodgkin lymphoma, Rev Assoc Med Bras, 68, 934, 10.1590/1806-9282.65.7.934

Georgianos, 2019, Acute interstitial nephritis in a patient with non-small cell lung cancer under immunotherapy with nivolumab, Case Rep Nephrol, 2019, 3614980

Manohar, 2019, Interstitial nephritis in immune checkpoint inhibitor therapy, Kidney Int, 96, 252, 10.1016/j.kint.2018.11.009

Shirali, 2016, Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients, Am J Kidney Dis, 68, 287, 10.1053/j.ajkd.2016.02.057

Thajudeen, 2015, Ipilimumab granulomatous interstitial nephritis, Am J Ther, 22, e84, 10.1097/MJT.0b013e3182a32ddc

Brahmer, 2018, Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline, J Clin Oncol, 36, 1714, 10.1200/JCO.2017.77.6385

Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, PLoS Med, 6, 10.1371/journal.pmed.1000097

Murad, 2018, Methodological quality and synthesis of case series and case reports, BMJ Evid Based Med, 23, 60, 10.1136/bmjebm-2017-110853

Wells

Ashour, 2019, Immune check point inhibitor-associated glomerulonephritis, Kid Int Rep, 4, 355, 10.1016/j.ekir.2018.10.017

Bickel, 2016, Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma, BMC Cancer, 16, 656, 10.1186/s12885-016-2718-y

Cho, 2019, Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial, J Clin Oncol, 37, 2162, 10.1200/JCO.2017.77.3184

Cortazar, 2020, Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study, J Am Soc Nephrol, 31, 435, 10.1681/ASN.2019070676

Gallan, 2019, Renal vasculitis and pauci-immune glomerulonephritis associated with immune checkpoint inhibitors, Am J Kidney Dis, 74, 853, 10.1053/j.ajkd.2019.04.016

Gao, 2018, Minimal change disease associated with anti-PD1 immunotherapy: a case report, BMC Nephrol, 19, 156, 10.1186/s12882-018-0958-6

Heo, 2017, Antineutrophil cytoplasmic antibody-associated rapid progressive glomerulonephritis after pembrolizumab treatment in thymic epithelial tumor: a case report, J Thorac Oncol, 12, e103, 10.1016/j.jtho.2017.03.011

Irifuku, 2020, Acute tubulointerstitial nephritis and IgM deposits on glomerular capillary walls after immunotherapy with nivolumab for metastatic renal cell carcinoma, CEN Case Rep, 9, 48, 10.1007/s13730-019-00424-1

Izzedine, 2019, Renal toxicities associated with pembrolizumab, Clin Kidney J, 12, 81, 10.1093/ckj/sfy100

Jung, 2016, Nivolumab-associated acute glomerulonephritis: a case report and literature review, BMC Nephrol, 17, 188, 10.1186/s12882-016-0408-2

Kidd, 2016, Ipilimumab-associated minimal-change disease, Kidney Int, 89, 720, 10.1016/j.kint.2015.11.028

Kishi, 2018, IgA nephropathy after nivolumab therapy for postoperative recurrence of lung squamous cell carcinoma, Intern Med, 57, 1259, 10.2169/internalmedicine.9814-17

Kitchlu, 2017, Nephrotic syndrome with cancer immunotherapies: a report of 2 cases, Am J Kidney Dis, 70, 581, 10.1053/j.ajkd.2017.04.026

Lemoine, 2019, Ipilimumab-induced renal granulomatous arteritis: a case report, BMC Nephrol, 20, 366, 10.1186/s12882-019-1552-2

Mamlouk, 2019, Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience, J Immunother Cancer, 7, 2, 10.1186/s40425-018-0478-8

Person, 2020, Severe acute kidney injury due to nivolumab/ipilimumab-induced granulomatosis and fibrinoid vascular necrosis, J Immunother, 43, 29

Takahashi, 2018, Goodpasture’s disease in a patient with advanced lung cancer treated with nivolumab: an autopsy case report, Lung Cancer, 122, 22, 10.1016/j.lungcan.2018.05.015

Ville, 2020, C3 glomerulonephritis in a patient treated with anti-PD-1 antibody, Eur J Cancer, 125, 46, 10.1016/j.ejca.2019.11.011

Oki, 2020, Renal effects after pembrolizumab treatment for non-small cell lung carcinoma: a case report, Intern Med, 59, 977, 10.2169/internalmedicine.3928-19

Saito, 2020, Re-administration of pembrolizumab with prednisolone after pembrolizumab-induced nephrotic syndrome, Eur J Cancer, 126, 74, 10.1016/j.ejca.2019.12.015

Daanen, 2017, Nivolumab-associated nephrotic syndrome in a patient with renal cell carcinoma: a case report, J Immunother, 40, 345

Lapman, 2020, Immune checkpoint inhibitor–associated renal amyloid A amyloidosis: a case series and review of the literature, Journal of Onco-Nephrology, 4, 10.1177/2399369320907598

Sammartino, 2009, Anti-GBM disease following CTLA4 blockade in a patient with metastatic melanoma, NDT Plus, 3, 135

Sprangers, 2019, Pembrolizumab-related renal toxicities: diagnosis first, treatment later, Clin Kidney J, 12, 78, 10.1093/ckj/sfy114

Fadel, 2009, Anti-CTLA4 antibody-induced lupus nephritis, N Engl J Med, 361, 211, 10.1056/NEJMc0904283

Chen, 2016, Gender-based differences and barriers in skin protection behaviors in melanoma survivors, J Skin Cancer, 2016, 3874572

Smalley, 2018, Why do women with melanoma do better than men?, Elife, 7, 10.7554/eLife.33511

Jhaveri, 2018, Adverse events associated with immune checkpoint blockade, N Engl J Med, 378, 1163, 10.1056/NEJMc1801663

Kitchlu, 2018, Representation of patients with chronic kidney disease in trials of cancer therapy, JAMA, 319, 2437, 10.1001/jama.2018.7260

Manohar, 2020, acute interstitial nephritis and checkpoint inhibitor therapy, Kidney360, 1, 16, 10.34067/KID.0000152019

Eijgelsheim, 2020, Kidney biopsy should be performed to document the cause of immune checkpoint inhibitor–associated acute kidney injury: pro, Kidney360, 1, 158, 10.34067/KID.0001192019

Gutgarts, 2020, Kidney biopsy should be performed to document the cause of immune checkpoint inhibitor–associated acute kidney injury: con, Kidney360, 1, 162, 10.34067/KID.0000132020

Perazella, 2020, Kidney biopsy should be performed to document the cause of immune checkpoint inhibitor–associated acute kidney injury: commentary, Kidney360, 1, 166, 10.34067/KID.0001072019

Thompson, 2019, Management of immunotherapy-related toxicities, version 1.2019, J Natl Compr Canc Netw, 17, 255, 10.6004/jnccn.2019.0013

Martinez Valenzuela, 2019, T-lymphocyte in ANCA-associated vasculitis: what do we know? A pathophysiological and therapeutic approach, Clin Kidney J, 12, 503, 10.1093/ckj/sfz029

Roth, 2013, Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis, J Clin Invest, 123, 1773, 10.1172/JCI65292

Zha, 2017, Blocking C5aR signaling promotes the anti-tumor efficacy of PD-1/PD-L1 blockade, Oncoimmunology, 6, 10.1080/2162402X.2017.1349587

Smith, 2019, C3 glomerulopathy - understanding a rare complement-driven renal disease, Nat Rev Nephrol, 15, 129, 10.1038/s41581-018-0107-2